Medication Interactions and Guidelines

Introduction to Medications

Cyclobenzaprine is an oral centrally acting 5-HT2 receptor antagonist that functions as a skeletal muscle relaxant, with anticholinergic effects including hallucinations, confusion, drowsiness, constipation, urinary retention, and dry mouth 1
The American College of Physicians recommends perioperative management of cyclobenzaprine, including holding the medication on the day of operation 1

Cyclobenzaprine works as a centrally acting muscle relaxant, with a different mechanism of action compared to minoxidil, which is a potassium channel opener and vasodilator that promotes hair growth 1
The most common adverse reactions of cyclobenzaprine include drowsiness, dizziness, dry mouth, and constipation 1
Minoxidil is a medication used for severe refractory hypertension and hair loss, with different formulations (oral and topical) having distinct safety profiles and monitoring requirements, as recommended by the American College of Cardiology 2

The American College of Cardiology recommends oral minoxidil for severe refractory hypertension at doses of 5-100 mg/day, with mandatory loop diuretic co-administration and consideration of beta-blocker co-administration due to sodium and water retention and reflex tachycardia 2
Oral minoxidil can cause significant side effects, including reflex tachycardia, sodium and water retention, hypertrichosis (excessive hair growth), and potential hypotension, as well as a risk of pericardial effusion, especially at higher doses 2
Patients with cardiovascular disease, history of pericardial effusion, severe renal impairment, or uncontrolled hypertension should use oral minoxidil with extreme caution, as recommended by the American College of Cardiology 2
Topical minoxidil has minimal systemic absorption (~1.4% of applied dose) and negligible cardiovascular effects when used as directed, with no requirement for cardiovascular monitoring needed for most patients, as stated by the American College of Cardiology 2
The recommended dosage for oral minoxidil in hypertension is 5-100 mg/day in 1-3 divided doses, with starting doses of ≤1 mg/day for women and ≤2.5 mg/day for men when used concurrently with nivolumab, as suggested by clinical guidelines 2, 3, 4

Baseline and periodic blood pressure measurements are necessary for patients using oral minoxidil, along with weight monitoring for fluid retention and consideration of baseline ECG, especially for higher doses, as recommended by the American College of Cardiology 2
Regular monitoring for potential cardiovascular effects, such as hypotension and tachycardia, is recommended when using oral minoxidil concurrently with nivolumab, with consideration of ECG monitoring if using higher doses, as stated by the American Society of Clinical Oncology (ASCO) 3, 4
Patients should be instructed to report any symptoms of dizziness, palpitations, unusual fatigue, swelling of extremities, and shortness of breath immediately, and healthcare providers should be aware of the potential for adverse effects, particularly in women who may require lower doses of minoxidil 1

The concurrent use of immune checkpoint inhibitors and vasodilators, such as oral minoxidil, appears to be safe with appropriate monitoring, as there are no documented significant drug interactions between these medications that would affect morbidity or mortality, as stated by the American Society of Clinical Oncology (ASCO) 3, 4
Concomitant use of buprenorphine (Suboxone) and QT-prolonging agents, such as minoxidil, requires careful monitoring due to the potential for QT interval prolongation, as stated in guidelines from the American College of Cardiology and Mayo Clinic Proceedings 1
Minoxidil should not be used concurrently with methadone due to the risk of QT interval prolongation and potential cardiac arrhythmias, as recommended by the American College of Cardiology 5
The combination of alfuzosin and oral minoxidil should be avoided in patients with severe heart failure, uncontrolled hypertension, history of pericardial effusion, and severe renal impairment, as recommended by the American Heart Association with a strength of evidence level of moderate 6, 7

Patients with cardiovascular disease should consider alternatives to oral minoxidil, and if necessary, ensure close monitoring, as recommended by the American College of Cardiology 6, 7
Elderly patients should use lower starting doses of medications, as recommended by the American Academy of Family Physicians 8
Patients with multiple sclerosis (MS) taking oral minoxidil should be instructed to report symptoms such as dizziness, lightheadedness, palpitations, unusual fatigue, swelling of extremities, and shortness of breath, with regular clinical follow-up to assess new symptoms and medication side effects, as recommended by the American College of Cardiology 9

The American Heart Association and American College of Cardiology acknowledge that some antihypertensive medications can have negative effects on libido and erectile function, but do not specifically identify minoxidil as problematic 10
The American College of Cardiology recommends that patients concerned about sexual side effects should be informed that oral minoxidil has limited evidence of sexual side effects compared to other antihypertensives like beta-blockers or thiazide diuretics 11
The American Heart Association and American College of Cardiology suggest that phosphodiesterase-5 inhibitors can be safely used with most antihypertensives, including minoxidil, for treating erectile dysfunction 10